BC Extra | Apr 18, 2017
Company News

Novartis, Allergan planning NASH combo trial

Novartis AG (NYSE:NVS; SIX:NOVN) and Allergan plc (NYSE:AGN) said they will test a combination including a farnesoid X receptor (FXR; NR1H4) agonist from Novartis and cenicriviroc (formerly TBR-652) from Allergan in a Phase IIb trial...
BioCentury | Oct 3, 2016
Strategy

Combo deals

Allergan plc's two NASH acquisitions give it the second biggest pipeline for the indication and enough mechanisms to develop in-house combinations that could target multiple drivers of the disease pathophysiology. Together, Allergan's Sept. 20 deals...
BC Week In Review | Sep 26, 2016
Company News

Akarna, Allergan deal

Allergan acquired Akarna for $50 million up front and undisclosed development, regulatory and sales milestones tied to lead asset AKN-083 , a farnesoid X receptor (FXR; NR1H4 ) agonist that is in preclinical development to treat non-alcoholic...
BC Extra | Sep 20, 2016
Top Story

Allergan acquiring NASH companies Tobira, Akarna

Allergan plc (NYSE:AGN) said Tuesday it had acquired a pair of companies with "complementary" assets to treat non-alcoholic steatohepatitis. Before market hours, it said it would buy Tobira Therapeutics Inc. (NASDAQ:TBRA). After market close, it...
Items per page:
1 - 4 of 4